XLO
Healthcare BiotechnologyXilio Therapeutics, Inc.
$9.01
+0.10 +1.12% today
Price History
Not enough data
Key Stats
Market Cap
59.29M
Avg Volume
23,031
EPS
-$0.60
52W High
$12.59
52W Low
$6.47
Div. Yield
0.0%
Analyst Ratings
Buy0
Str Buy
1
Buy
0
Hold
0
Sell
0
Str Sell
Valuation
Forward P/E
-15.53
P/B Ratio
1.16
P/S Ratio
0.93
EV/EBITDA
2.35
EV/Revenue
-1.10
Margins
Gross Margin 83.2%
Operating Margin (18.7%)
Net Margin (34.1%)
EBITDA Margin (46.9%)
Growth & Returns
Revenue Growth (YoY)
131.2%
Return on Equity
(55.0%)
Return on Assets
(13.6%)
Liquidity & Leverage
Current Ratio
4.25
Quick Ratio
4.15
Debt / Equity
0.09
Total Cash
136.04M
Total Debt
6.30M
About
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company's pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors; and Vilastobart, an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.
xiliotx.com